OrbiMed Advisors acquires $10 million of BlossomHill Therapeutics common shares - BLSM News | RalliesOrbiMed Advisors acquires $10 million of BlossomHill Therapeutics common shares
B
BLSM• OrbiMed increases indirect holding in BlossomHill Therapeutics
- OrbiMed Advisors reported a higher stake in BlossomHill Therapeutics, ending with 2,714,279 shares of common stock held indirectly.
- The position increase reflected 625,000 shares bought in the IPO at $16.
- Holdings also rose through conversion of Series A and Series B preferred stock into 2,089,279 common shares.
